440 related articles for article (PubMed ID: 32457020)
1. Meta-Analysis of the Efficacy and Safety of P2Y
Elzanaty AM; Nazir S; Awad MT; Elsheikh E; Ahuja KR; Donato A; Eltahawy EA
Cardiovasc Revasc Med; 2020 Dec; 21(12):1500-1506. PubMed ID: 32457020
[TBL] [Abstract][Full Text] [Related]
2. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.
Giacoppo D; Matsuda Y; Fovino LN; D'Amico G; Gargiulo G; Byrne RA; Capodanno D; Valgimigli M; Mehran R; Tarantini G
Eur Heart J; 2021 Jan; 42(4):308-319. PubMed ID: 33284979
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials.
Garg A; Rout A; Sharma A; Sargsyan D; Beavers T; Tantry U; Gurbel P; Rao SV; Kostis JB; Cohen M
Prog Cardiovasc Dis; 2020; 63(3):243-248. PubMed ID: 32247786
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of short-term (1 to 3 months) dual antiplatelet therapy in patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials.
Kheiri B; Simpson TF; Osman M; Golwala H; Radaideh Q; Kumar K; Rahmouni H; Divanji P; Cigarroa JE; Zahr F
J Thromb Thrombolysis; 2020 Nov; 50(4):867-873. PubMed ID: 32607653
[TBL] [Abstract][Full Text] [Related]
5. P2Y12 Inhibitor Monotherapy After a Short Dual Antiplatelet Therapy Versus Standard-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Meta-Analysis.
Ho AC; Egolum U; Parker S; Dimmel J; Hawkins A; Ling H
Clin Drug Investig; 2020 Sep; 40(9):799-808. PubMed ID: 32661914
[TBL] [Abstract][Full Text] [Related]
6. P2Y
Gragnano F; Mehran R; Branca M; Franzone A; Baber U; Jang Y; Kimura T; Hahn JY; Zhao Q; Windecker S; Gibson CM; Kim BK; Watanabe H; Song YB; Zhu Y; Vranckx P; Mehta S; Hong SJ; Ando K; Gwon HC; Calabrò P; Serruys PW; Dangas GD; McFadden EP; Angiolillo DJ; Heg D; Valgimigli M;
J Am Coll Cardiol; 2023 Feb; 81(6):537-552. PubMed ID: 36754514
[TBL] [Abstract][Full Text] [Related]
7. Abbreviated Dual Antiplatelet Therapy Followed by P2Y
Kumar A; Shariff M; Doshi R; Vaz IP
Am J Cardiovasc Drugs; 2020 Aug; 20(4):355-361. PubMed ID: 31784888
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of Dual Antiplatelet Therapy Versus Monotherapy With P2Y12 Inhibitors in Patients After Percutaneous Coronary Intervention.
Malik AH; Yandrapalli S; Shetty SS; Aronow WS; Cooper HA; Panza JA
Am J Cardiol; 2020 Jul; 127():25-29. PubMed ID: 32389351
[TBL] [Abstract][Full Text] [Related]
9. P2Y12 inhibitors monotherapy after short course of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials including 29 089 patients.
Bianco M; Careggio A; Destefanis P; Luciano A; Perrelli MG; Quadri G; Rossini R; Campo G; Vizzari G; D'Ascenzo F; Anselmino M; Biondi-Zoccai G; Ibáñez B; Montagna L; Varbella F; Cerrato E
Eur Heart J Cardiovasc Pharmacother; 2021 May; 7(3):196-205. PubMed ID: 32544220
[TBL] [Abstract][Full Text] [Related]
10. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
; Bittl JA; Baber U; Bradley SM; Wijeysundera DN
Circulation; 2016 Sep; 134(10):e156-78. PubMed ID: 27026019
[TBL] [Abstract][Full Text] [Related]
11. Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis.
Khan SU; Singh M; Valavoor S; Khan MU; Lone AN; Khan MZ; Khan MS; Mani P; Kapadia SR; Michos ED; Stone GW; Kalra A; Bhatt DL
Circulation; 2020 Oct; 142(15):1425-1436. PubMed ID: 32795096
[TBL] [Abstract][Full Text] [Related]
12. Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.
Feng WH; Chang YC; Lin YH; Chen HL; Chang HM; Chu CS
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562942
[TBL] [Abstract][Full Text] [Related]
13. Short-term dual antiplatelet therapy (DAPT) followed by P2Y12 monotherapy versus traditional DAPT in patients undergoing percutaneous coronary intervention: meta-analysis and viewpoint.
Wernly B; Rezar R; Gurbel P; Jung C
J Thromb Thrombolysis; 2020 Jan; 49(1):173-176. PubMed ID: 31686298
[TBL] [Abstract][Full Text] [Related]
14. Maintained P2Y
Fan ZG; Tian NL; He SH; Ma GS
J Clin Pharm Ther; 2022 Jul; 47(7):860-869. PubMed ID: 35218029
[TBL] [Abstract][Full Text] [Related]
15. P2y
Yu Y; Pan D; Bai R; Luo J; Tan Y; Duan W; Shi D
Front Cardiovasc Med; 2023; 10():1197161. PubMed ID: 37485257
[TBL] [Abstract][Full Text] [Related]
16. Effect of P2Y12 inhibitor monotherapy versus dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: systematic review and meta-analysis.
Wu XT; He RR; Liang SZ; Ye GY; Ding SB
Minerva Med; 2020 Apr; 111(2):173-180. PubMed ID: 32338843
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of P2Y
Casula M; Casu G; Talanas G; Spano A; Tantry U; Bilotta F; Micheluzzi V; Merella P; Porcheddu T; Gorog DA; Bonaca M; Jeong YH; Farkouh ME; Kubica J; Isgender M; Gurbel PA; Navarese EP
Curr Probl Cardiol; 2024 Aug; 49(8):102635. PubMed ID: 38750991
[TBL] [Abstract][Full Text] [Related]
18. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
Hahn JY; Song YB; Oh JH; Chun WJ; Park YH; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
JAMA; 2019 Jun; 321(24):2428-2437. PubMed ID: 31237645
[TBL] [Abstract][Full Text] [Related]
19. P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent: The SHARE Randomized Clinical Trial.
Min PK; Kang TS; Cho YH; Cheong SS; Kim BK; Kwon SW; Park WJ; Lee JH; Kim W; Lee WS; Yoon YW; Lee BK; Kwon HM; Hong BK;
JAMA Netw Open; 2024 Mar; 7(3):e240877. PubMed ID: 38451525
[TBL] [Abstract][Full Text] [Related]
20. Benefits of short-term or prolonged as compared to standard 1 year DAPT in patients with acute coronary syndrome treated with drug-eluting stents: a meta-analysis of 9 randomized trials.
Verdoia M; Kedhi E; Suryapranata H; Frati G; Biondi-Zoccai G; De Luca G
J Thromb Thrombolysis; 2020 Aug; 50(2):337-354. PubMed ID: 31919736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
